The Business Research Company’s report on the Bipolar Disorder Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the bipolar disorder therapeutics industry?
The increasing healthcare expenditure is expected to propel the growth of the bipolar disorder therapeutics market going forward. Healthcare infrastructure refers to all costs or outlays for medical care, preventative measures, public health initiatives, rehabilitation, community health activities, and health research. Increasing healthcare expenditure can be attributed to several factors, including an aging population, a rise in chronic diseases, and higher drug costs, all of which significantly contribute to the growing demand for medical services and treatments. As awareness of mental health issues rises, the diagnosis of bipolar disorder increases, leading to a higher demand for therapeutic interventions. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health spending in Canada is anticipated to rise by 2.8% in 2023, following a modest growth of just 1.5% in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the bipolar disorder therapeutics market.
Access Your Free Sample of the Global Bipolar Disorder Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=6736&type=smp
What is the estimated market size of the bipolar disorder therapeutics sector by 2029, based on current forecasts?
The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.44 billion in 2024 to $7.89 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to rise in medical research and developments, increased healthcare expenditure, rise in prevalence of mental health disorders, rise in patient advocacy.
The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing prevalence of bipolar disorder, government initiatives, expansion of healthcare infrastructure, growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, digital health integration, innovative medications, preventive interventions, neuroimaging and biomarkers.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=6736&type=smp
#Who are the top players in the bipolar disorder therapeutics market?
Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc, AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd, H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.
#What are the major trends in the bipolar disorder therapeutics market?
Strategic partnerships have emerged as a key trend gaining popularity in the bipolar disorder therapeutics market. Major companies operating in the bipolar disorder therapeutics sector are focused on partnerships to reinforce their position. For instance, in April 2022, BioXcel Therapeutics, Inc., a US-based biopharmaceutical company, approved IGALMITM (dexmedetomidine), a specifically FDA-approved sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. that dissolves in the mouth, specifically formulated for addressing mild, moderate, or severe agitation in these patient groups. The drug is designed for a rapid onset of action, enabling effective management of agitation episodes.
Which geography holds the highest bipolar disorder therapeutics market share?
North America was the largest region in the bipolar disorder therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report
How do different segments contribute to the overall expansion of the bipolar disorder therapeutics market?
The bipolar disorder therapeutics market covered in this report is segmented –
1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs
2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Other Mechanisms
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Mood Stabilizers: Lithium, Anticonvulsants, Calcium Channel Blockers
2) By Antipsychotic Drugs: Atypical Antipsychotics, Typical Antipsychotics
3) By Antidepressant Drugs: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs)
4) By Other Drugs: Benzodiazepines, Adjunctive Therapies, Herbal Supplements
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6736
How is the bipolar disorder therapeutics market defined?
Bipolar disorder therapeutics refer to medication, including mood stabilizers, antidepressants, antipsychotics, and psychological counseling, to control symptoms. The bipolar disorder therapeutic is used in the treatment and management of bipolar disorders.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
